secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-08-14T20:06:03+00:00
Accession:  0001104659-26-097094
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Q2 net loss $5.4M; FDA clears first-ever IND for Peeling Skin Syndrome
----------------------------------------------------------------------------

- Q2 2026 net loss $5.4M vs $3.7M in Q2 2025; six-month loss $10.4M vs $7.5M.
- Cash, equivalents, and marketable securities $10.8M as of June 30, 2026; funds operations into 2027.
- FDA conditionally approved QYLEKI as brand name for QRX003 (Netherton Syndrome) on June 23, 2026.
- FDA cleared IND for QRX003 in Peeling Skin Syndrome on July 9, 2026; Phase 2/3 study to start 2H 2026.
- USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome on June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/0001104659-26-097094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/tm2623115d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-097094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer